Physician profile
Robert L Barrett
NPI 1477553436
$4,112.04
in general payments reported to CMS, 2019-2025
26 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $445 · 2021: $505 · 2022: $987 · 2023: $229 · 2024: $297 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098 · Gift: $47.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.37 |
| Gift | $47.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $879.81 | 2019-2025 | Impella |
| Medtronic, INC. | $628.32 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Resolute Onyx |
| Boston Scientific Corporation | $441.23 | 2019-2025 | Intracept |
| Janssen Pharmaceuticals, INC | $382.67 | 2019-2023 | Xarelto |
| Amgen INC. | $171.22 | 2021-2023 | Repatha |
| Kestra Medical Technology Services, INC. | $166.88 | 2024-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $154.31 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.69 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $148.92 | 2020-2024 | Farxiga |
| Siemens Medical Solutions USA, INC. | $132.25 | 2019 | |
| Amarin Pharma, INC. | $124.96 | 2019-2021 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Medtronic Vascular, INC. | $97.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $88.99 | 2022-2023 | Verquvo |
| Philips North America LLC | $84.58 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.56 | 2022-2025 | Lifevest |
| Cvrx, INC. | $56.02 | 2022-2025 | Barostim Neo System |
| Novo Nordisk INC | $39.48 | 2024-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $38.34 | 2019-2024 | |
| Esperion Therapeutics, INC. | $36.48 | 2021-2022 | |
| Pfizer INC. | $30.18 | 2023 | |
| Lilly USA, LLC | $18.12 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $17.81 | 2021 | |
| Inspire Medical Systems, INC. | $16.20 | 2025 | Inspire |
| Cardiovascular Systems INC. | $15.54 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.